GFO Issue 110, Article Number: 2
Sub-title :
News
Author:
Bernard Rivers
Date:
2009-11-12
ABSTRACT
ABSTRACT
Details are provided of the Board's decision regarding each eligible Round 9 proposal.
Based on advice from the TRP, the Board divided eligible Round 9 proposals into five Categories, as follows:
- Category 1: Approved proposals requiring no or minor clarifications, which need to be provided within 8 weeks and then given a final approval by the TRP Chair and/or Vice-Chair.
- Category 2: Proposals that are approved in principle, subject to the required clarifications being provided within a limited timeframe (8 weeks for the applicant to provide an initial detailed response to the TRP queries, and a further 3 months to obtain the final TRP approval should further clarifications be requested). The TRP Chair and Vice-Chair need to give final approval.
- Category 2B: Proposals that are treated as those in Category 2, but are regarded as being relatively weak, on grounds of technical merit and/or issues of feasibility and likelihood of effective implementation.
- Category 3: Proposals not approved in their present form, though applicants are encouraged to resubmit in Round 10 following major revision.
- Category 4: Proposals that are rejected, with applicants not encouraged to resubmit in any similar form.
The Board approved "in principle" all proposals in Categories 1, 2 and 2B. However, some of the approvals are immediate and some are delayed, depending on future availability of funds. The prioritization is handled as follows:
- Category 1 and Category 2 proposals are approved immediately.
- Each country submitting a proposal rated Category 2B is assigned a disease burden index of 4 or 1 according to whether the disease burden is "very high" or not "very high". And each such country is assigned a poverty index of 4, 2 or 0 according to whether the country is low income, lower-middle income, or upper-middle income. The sum of these two indexes creates the Composite Index, whose value is therefore between 8 and 1. The higher the country's Composite Index, the sooner its Category 2B proposal will be approved.
- Category 2B proposals will be approved in the following order, as pledges by donors to the Fund become available in the course of 2009-2010:
- Category 2B, Composite Index 8
- Category 2B, Composite Index 6
- Category 2B, Composite Index 5
- Category 2B, Composite Index 4
- Category 2B, Composite Index 3
The number of Round 9 grants per Category and Composite Index are as follows:
Table 5: Round 9 results by Category and Composite Index
Category and Composite Index
Number of proposals
Amount
requested (Years 1-2)
Immediate approval: Category 1
5
$0.14 b.
Immediate approval: Category 2
49
$1.35 b.
Delayed approval: Category 2B, Composite Index 8
9
$0.32 b.
Delayed approval: Category 2B, Composite Index 6
6
$0.17 b.
Delayed approval: Category 2B, Composite Index 5
6
$0.15 b.
Delayed approval: Category 2B, Composite Index 4
1
$0.00 b.
Delayed approval: Category 2B, Composite Index 3
9
$0.08 b.
Subtotal: All Approved Proposals:
85
$2.21 b.
Not Approved: Category 3
64
$2.08 b.
Not Approved: Category 4
10
$0.19 b.
Not Approved: Removed sub-components of approved proposals
n/a
$0.37 b.
Subtotal: All Non-Approved Proposals:
74
$2.63 b.
Total: All Proposals
159
$4.85 b.
Round 9 results by applicant were as in Tables 6 and 7, below.
Table 6: Round 9 Results, by Country
Note that for each grant, the final amount that will be approved will be on average at least 10% lower than the amount requested for years 1-2, and potentially up to 25% lower for years 3-5.
Country
Disease component
Applicant type
Decision
Category
(defined above)
Composite Index
(defined above)
Amount
requested (Years 1-2)
Amount requested (Years 1-5)
Afghanistan
HIVÂ (disease part + HSS part)
CCM
Not approved
3
n/a
USD17,157,661
USD48,857,724
Albania
HIV
CCM
Not approved
3
n/a
USD8,097,017
USD13,275,254
Albania
TB
CCM
Not approved
3
n/a
USD2,482,523
USD5,226,962
Angola
HIV
CCM
Not approved
3
n/a
USD37,442,140
USD138,112,093
Angola
TB
CCM
Delayed approval
2B
6
USD11,384,314
USD25,766,362
Azerbaijan
HIV
CCM
Immediate approval
2
n/a
EUR11,831,706
EUR26,983,960
Azerbaijan
TB
CCM
Immediate approval
2
n/a
EUR1,983,042
EUR5,065,216
Bangladesh
Malaria
CCM
Immediate approval
2
n/a
USD10,280,071
USD43,649,545
Belarus
TB
CCM
Immediate approval
2
n/a
USD10,127,774
USD24,679,591
Belize
HIVÂ (disease part + HSS part)
CCM
Delayed approval
2B
4
USD3,190,410
USD6,053,270
Benin
HIVÂ (disease part + HSS part)
CCM
Immediate approval
2
n/a
EUR48,272,734
EUR108,636,826
Benin
TB
CCM
Immediate approval
2
n/a
EUR2,813,599
EUR4,815,146
Bhutan
HIV
CCM
Not approved
3
n/a
USD1,277,902
USD3,429,344
Bolivia
HIV
CCM
Immediate approval
2
n/a
USD9,501,866
USD26,267,794
Bolivia
TB
CCM
Immediate approval
2
n/a
USD4,379,037
USD9,833,163
Bosnia & Herzegovina
HIV
CCM
Immediate approval
2
n/a
EUR14,428,659
EUR32,453,777
Bosnia & Herzegovina
TB
CCM
Delayed approval
2B
3
EUR7,287,274
EUR15,007,449
Botswana
HIV
CCM
Not approved
3
n/a
USD22,137,763
USD75,677,032
Brazil
TB
CCM
Not approved
3
n/a
EUR26,499,742
EUR57,157,477
Brazil
HIV
CCM
Not approved
3
n/a
EUR13,097,142
EUR30,940,720
Burkina Faso
HIVÂ (disease part + HSS part)
CCM
Not approved
3
n/a
EUR49,925,705
EUR160,561,226
Burundi
Malaria
CCM
Immediate approval
2
n/a
USD21,578,809
USD60,448,200
Cambodia
HIVÂ (disease part + HSS part)
CCM
Immediate approval
2
n/a
USD63,502,281
USD165,087,396
Cambodia
Malaria
CCM
Immediate approval
1
n/a
USD43,717,857
USD102,033,561
Cameroon
HIV
CCM
Not approved
3
n/a
EUR41,336,332
EUR121,255,912
Cameroon
Malaria
CCM
Immediate approval
2
n/a
EUR77,791,996
EUR113,983,337
Cameroon
TB
CCM
Immediate approval
2
n/a
EUR6,823,011
EUR15,422,473
Central African Republic
TB
CCM
Delayed approval
2B
8
EUR12,167,295
EUR29,782,006
Chad
HIVÂ (disease part + HSS part)
CCM
Not approved
3
n/a
EUR36,087,457
EUR57,040,882
Chad
Malaria
CCM
Immediate approval
2
n/a
EUR20,807,913
EUR29,993,968
Chad
TB
CCM
Not approved
3
n/a
EUR4,409,888
EUR8,658,158
China *
TBÂ (disease part + HSS part)
CCM
Delayed approval
2B
6
USD76,075,195
USD239,655,469
Colombia
HIV
CCM
Delayed approval
2B
6
EUR16,659,253
EUR42,317,779
Colombia
TB
CCM
Not approved
3
n/a
EUR6,981,414
EUR13,155,213
Comoros
HIVÂ (disease part + HSS part)
CCM
Immediate approval
2
n/a
EUR1,833,520
EUR3,107,636
Congo (Democratic Republic of)
HIV
CCM
Not approved
3
n/a
USD42,987,274
USD94,181,440
Congo (Democratic Republic of)
Malaria
CCM
Not approved
3
n/a
USD117,708,841
USD280,495,135
Congo (Democratic Republic of)
TBÂ (disease part + HSS part)
CCM
Delayed approval
2B
8
USD110,092,302
USD306,794,269
Congo (Republic of)
HIV
CCM
Delayed approval
2B
6
EUR10,773,466
EUR27,447,268
Cote d'Ivoire
HIVÂ (disease part)
CCM
Immediate approval
2
n/a
EUR46,066,302
EUR125,953,322
Cote d'Ivoire
HIVÂ (HSS part)
CCM
Not approved
n/a
n/a
EUR43,810,725
EUR97,590,298
Cote d'Ivoire
TB
CCM
Immediate approval
2
n/a
EUR9,672,256
EUR33,977,331
Djibouti
HIV
CCM
Not approved
3
n/a
EUR4,609,238
EUR15,739,214
Djibouti
Malaria
CCM
Delayed approval
2B
3
EUR2,342,193
EUR6,591,356
Djibouti
TB
CCM
Not approved
3
n/a
EUR1,847,708
EUR5,069,930
Dominican Republic
HIV
CCM
Not approved
3
n/a
USD16,796,759
USD49,481,694
Ecuador
HIV
CCM
Immediate approval
2
n/a
USD10,813,915
USD27,922,499
Ecuador
TB
CCM
Immediate approval
2
n/a
USD6,834,160
USD13,736,572
El Salvador
TB
CCM
Immediate approval
2
n/a
USD3,588,887
USD7,810,938
Eritrea
Malaria (disease part + HSS part)
CCM
Immediate approval
1
n/a
USD29,855,990
USD69,433,635
Ethiopia
HIV
CCM
Not approved
3
n/a
USD38,910,498
USD87,776,761
Ethiopia
TBÂ (disease part)
CCM
Not approved
n/a
n/a
USD35,441,974
USD99,748,261
Ethiopia
TBÂ (HSS part)
CCM
Delayed approval
2B
8
USD19,383,242
USD38,601,776
Fiji
HIVÂ (disease part)
CCM
Not approved
n/a
n/a
USD4,567,641
USD11,032,725
Fiji
HIVÂ (HSS part)
CCM
Immediate approval
2
n/a
USD1,242,510
USD2,075,508
Gambia
Malaria
CCM
Immediate approval
2
n/a
USD10,611,436
USD26,346,040
Gambia
TB
CCM
Delayed approval
2B
5
USD8,049,144
USD15,626,486
Georgia
HIV
CCM
Immediate approval
1
n/a
EUR7,209,605
EUR12,826,501
Georgia
TB
CCM
Not approved
3
n/a
EUR6,334,105
EUR15,198,017
Ghana
TBÂ (disease part + HSS part)
CCM
Not approved
3
n/a
USD35,221,971
USD78,630,160
Guatemala
Malaria
CCM
Immediate approval
2
n/a
USD21,452,001
USD42,171,298
Guinea
Malaria
CCM
Not approved
3
n/a
USD41,713,830
USD136,406,368
Guinea
TB
CCM
Immediate approval
2
n/a
USD4,035,589
USD10,736,627
Guinea
HIVÂ (disease part + HSS part)
CCM
Not approved
3
n/a
USD47,536,996
USD133,700,829
Guinea-Bissau
Malaria (disease part + HSS part)
CCM
Immediate approval
2
n/a
EUR6,145,091
EUR13,492,563
Guinea-Bissau
TB
CCM
Delayed approval
2B
5
EUR7,179,501
EUR14,553,382
Haiti
TB
CCM
Delayed approval
2B
8
USD12,260,870
USD27,669,547
Honduras
HIV
CCM
Immediate approval
2
n/a
USD9,821,491
USD21,899,375
Honduras
TB
CCM
Not approved
3
n/a
USD4,644,621
USD7,973,129
India
HIV
CCM
Delayed approval
2B
8
USD21,000,206
USD78,712,640
India
Malaria
CCM
Delayed approval
2B
5
USD38,105,605
USD113,680,179
India
TB
CCM
Immediate approval
2
n/a
USD69,477,410
USD199,544,948
Indonesia
HIVÂ (disease part)
CCM
Immediate approval
2
n/a
USD27,723,275
USD87,142,130
Indonesia
HIVÂ (HSS part)
CCM
Not approved
n/a
n/a
USD16,211,864
USD34,683,394
Iraq
TB
CCM
Delayed approval
2B
3
USD14,670,783
USD28,785,292
Kenya
Malaria
CCM
Not approved
3
n/a
USD173,151,886
USD270,264,819
Kenya *
TB
CCM
Delayed approval
2B
8
USD23,682,114
USD50,661,608
Korea (Democratic People's Republic of)
HIV
CCM
Not approved
4
n/a
EUR3,621,666
EUR10,260,105
Kosovo
TB
CCM
Delayed approval
2B
3
EUR2,784,907
EUR5,821,665
Kyrgyz Republic
TB
CCM
Delayed approval
2B
5
USD7,811,886
USD26,273,558
Lesotho
HIV
CCM
Immediate approval
2
n/a
USD10,356,112
USD30,796,293
Liberia
TB
CCM
Not approved
3
n/a
USD24,337,864
USD54,637,458
Macedonia, FYR
TB
CCM
Not approved
3
n/a
EUR2,406,848
EUR4,846,058
Malawi
Malaria
CCM
Immediate approval
2
n/a
USD33,170,946
USD94,006,593
Malawi
TBÂ (disease part + HSS part)
CCM
Not approved
3
n/a
USD16,586,861
USD34,091,794
Malaysia
HIV
CCM
Not approved
3
n/a
EUR16,914,686
EUR55,470,594
Mali
Malaria
CCM
Not approved
3
n/a
EUR78,261,962
EUR174,578,758
Mexico
HIV
CCM
Immediate approval
2
n/a
USD31,008,826
USD76,492,174
Moldova
HIV
CCM
Not approved
3
n/a
EUR6,632,255
EUR6,632,255
Moldova
TB
CCM
Delayed approval
2B
3
EUR5,271,784
EUR10,099,233
Mongolia
HIVÂ (disease part)
CCM
Not approved
n/a
n/a
USD2,117,412
USD5,236,283
Mongolia
HIVÂ (HSS part)
CCM
Immediate approval
2
n/a
USD2,780,049
USD4,223,964
Montenegro
HIV
CCM
Delayed approval
2B
3
EUR2,547,414
EUR5,164,889
Montenegro
TB
CCM
Not approved
3
n/a
EUR1,079,081
EUR1,825,708
Mozambique
HIVÂ (disease part)
CCM
Delayed approval
2B
8
USD69,377,979
USD175,774,009
Mozambique
HIVÂ (HSS part)
CCM
Not approved
n/a
n/a
USD32,700,132
USD87,121,662
Mozambique
Malaria
CCM
Immediate approval
2
n/a
USD67,401,102
USD157,490,802
Myanmar
HIV
CCM
Immediate approval
1
n/a
USD51,716,207
USD157,776,471
Myanmar
Malaria
CCM
Immediate approval
2
n/a
USD37,578,282
USD77,384,020
Myanmar
TB
CCM
Immediate approval
2
n/a
USD34,024,424
USD85,520,947
Nepal
HIV
CCM
Not approved
3
n/a
USD10,250,156
USD33,295,636
Nicaragua
Malaria
CCM
Delayed approval
2B
3
USD4,299,868
USD8,204,092
Niger
HIV
CCM
Not approved
3
n/a
EUR12,273,273
EUR35,668,229
Niger
Malaria
CCM
Not approved
3
n/a
EUR14,774,509
EUR60,296,247
Niger
TBÂ (disease part + HSS part)
CCM
Not approved
3
n/a
EUR28,683,728
EUR51,445,595
Nigeria
HIV
CCM
Immediate approval
2
n/a
USD61,980,496
USD341,019,908
Nigeria
TB
CCM
Delayed approval
2B
8
USD31,515,160
USD113,332,101
Pakistan
HIVÂ (disease part + HSS part)
CCM
Not approved
3
n/a
USD34,771,776
USD101,928,849
Pakistan
Malaria
CCM
Not approved
3
n/a
USD22,058,072
USD38,444,514
Pakistan
TB
CCM
Immediate approval
2
n/a
USD40,146,549
USD173,045,676
Panama
HIVÂ (disease part + HSS part)
CCM
Not approved
3
n/a
USD8,681,679
USD19,791,821
Papua New Guinea
HIVÂ (disease part + HSS part)
CCM
Not approved
3
n/a
USD37,755,778
USD108,875,287
Paraguay
HIVÂ (disease part)
CCM
Not approved
n/a
n/a
USD6,924,331
USD16,738,249
Paraguay
HIVÂ (HSS part)
CCM
Immediate approval
2
n/a
USD6,463,831
USD12,735,212
Paraguay
TB
CCM
Immediate approval
2
n/a
USD2,080,336
USD3,974,941
Peru
Malaria
CCM
Not approved
3
n/a
EUR12,287,854
EUR23,978,876
Russian Federation
TB
CCM
Not approved
4
n/a
EUR39,148,932
EUR139,266,200
Russian Federation
TB
Sub-CCM
Not approved
4
n/a
EUR25,586,216
EUR46,500,983
São Tomé and PrÃncipe
HIV
CCM
Not approved
3
n/a
USD3,388,782
USD5,893,968
Senegal *
HIVÂ (disease part + HSS part)
CCM
Immediate approval
2
n/a
EUR29,125,467
EUR88,751,831
Senegal
Malaria
CCM
Not approved
3
n/a
EUR13,463,444
EUR43,391,628
Senegal
TB
CCM
Not approved
3
n/a
EUR5,439,361
EUR15,223,424
Serbia *
TB
CCM
Immediate approval
1
n/a
USD3,441,632
USD7,540,351
Sierra Leone
HIVÂ (disease part + HSS part)
CCM
Immediate approval
2
n/a
USD35,159,372
USD86,543,306
Sierra Leone
Malaria
CCM
Not approved
3
n/a
USD46,897,411
USD121,926,865
Solomon Islands
HIV
CCM
Not approved
3
n/a
USD6,896,921
USD17,219,358
South Africa
HIV
CCM
Immediate approval
2
n/a
USD42,577,518
USD108,974,360
Sri Lanka
HIVÂ (disease part + HSS part)
CCM
Delayed approval
2B
3
USD19,398,656
USD34,901,359
Sudan South
HIVÂ (disease part)
Sub-CCM
Not approved
n/a
n/a
USD59,977,815
USD143,281,740
Sudan South
HIVÂ (HSS part)
Sub-CCM
Immediate approval
2
n/a
USD27,230,100
USD52,572,614
Sudan South
Malaria
CCM
Not approved
3
n/a
USD47,848,374
USD130,852,071
Suriname
HIV
CCM
Not approved
3
n/a
USD13,973,874
USD30,918,273
Suriname
TB
CCM
Immediate approval
2
n/a
USD3,112,254
USD5,765,300
Syria
HIVÂ (disease part + HSS part)
CCM
Not approved
4
n/a
USD12,748,562
USD25,664,260
Syria
TB
CCM
Not approved
4
n/a
USD4,632,686
USD9,343,366
Tanzania
HIVÂ (disease part)
CCM
Not approved
n/a
n/a
USD141,703,169
USD299,064,874
Tanzania
HIVÂ (HSS part)
CCM
Immediate approval
2
n/a
USD97,901,945
USD176,089,978
Tanzania
Malaria
CCM
Delayed approval
2B
5
USD76,050,523
USD173,612,609
Tanzania
TB
CCM
Not approved
3
n/a
USD44,045,185
USD99,426,802
Thailand
HIV
CCM
Not approved
3
n/a
USD22,903,685
USD68,935,356
Thailand
Malaria
CCM
Not approved
3
n/a
USD32,327,332
USD75,648,892
Togo
HIV
CCM
Not approved
3
n/a
EUR19,855,192
EUR54,839,797
Togo
Malaria (disease part)
CCM
Immediate approval
2
n/a
EUR41,116,176
EUR70,116,448
Togo
Malaria (HSS part)
CCM
Not approved
n/a
n/a
EUR2,424,256
EUR5,369,974
Togo
TB
CCM
Not approved
4
n/a
EUR1,904,955
EUR1,904,955
Turkmenistan
TBÂ (disease part)
CCM
Delayed approval
2B
3
USD7,268,169
USD19,186,023
Turkmenistan
TBÂ (HSS part)
CCM
Not approved
n/a
n/a
USD181,777
USD289,542
Uganda
HIV
CCM
Not approved
3
n/a
USD200,824,716
USD411,140,514
Uganda
Malaria (disease part + HSS part)
CCM
Not approved
3
n/a
USD135,054,987
USD376,353,583
Uganda
TB
CCM
Not approved
3
n/a
USD20,327,175
USD32,684,978
Ukraine
TB
CCM
Not approved
3
n/a
USD34,584,205
USD103,459,618
Uruguay
HIV
CCM
Not approved
3
n/a
USD7,679,330
USD24,664,893
Vietnam *
HIV
CCM
Immediate approval
2
n/a
USD27,363,443
USD101,950,596
Vietnam
TB
CCM
Delayed approval
2B
8
USD19,124,977
USD59,392,208
Yemen
HIV
CCM
Not approved
3
n/a
USD10,943,780
USD25,246,321
Yemen
TB
CCM
Delayed approval
2B
5
USD11,136,828
USD24,769,339
Zambia
HIV
CCM
Not approved
3
n/a
USD26,111,595
USD142,597,930
Zambia
Malaria
CCM
Not approved
3
n/a
USD21,843,651
USD54,966,386
* Note that for Kenya TB, Senegal HIV, Serbia TB and Vietnam HIV, the amount requested is less than was in the proposal because the TRP removed certain elements from the proposal. Also for China TB the recommended amount was adjusted for other technical reasons.
Table 7: Round 9 results for regional applicants
Applicant
Disease
Applicant type
Decision
Category
(defined above)
Composite Index
(defined above)
Requested (Years 1-2)
Requested (Years 1-5)
AfriCASOÂ (re Benin, Cameroon, Central African Republic, Gabon, Gambia, Liberia)
HIV
Regional organisation
Not approved
3
n/a
EUR5,894,744
EUR13,672,440
Andean Regional Coordinating Mechanism (re Chile, Peru, Colombia, Bolivia, Ecuador, Venezuela)
HIV
Regional Coordinating Mechanism
Not approved
4
n/a
EUR19,820,520
EUR40,189,363
CCLABÂ (re Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama)
HIV
Regional Coordinating Mechanism
Not approved
3
n/a
USD11,123,412
USD18,721,697
COPRECOS LACÂ (re Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Nicaragua, Panama, Paraguay, Peru, Uruguay, Venezuela)
HIV
Regional organisation
Delayed approval
2B
6
USD17,599,678
USD58,889,550
Mano River Union (re Côte d'Ivoire, Guinea, Liberia, Sierra Leone)
HIV
Regional organisation
Not approved
4
n/a
USD21,688,571
USD36,300,171
MENAHRAÂ (re Afghanistan, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, West Bank and Gaza, Pakistan, Syrian Arab Republic, Tunisia)
HIV
Regional organisation
Not approved
3
n/a
USD15,196,689
USD32,966,023
Naz Foundation Int. (re Afghanistan, Bangladesh, Bhutan, India, Nepal, Pakistan, Sri Lanka)
HIV
Regional organisation
Immediate approval
2
n/a
USD18,660,775
USD47,002,257
PANCAP-CARICOMÂ (re Haiti, Dominican Republic, Guyana, Jamaica, Suriname, Belize, Dominica, Grenada, St. Lucia, St Vincent and the Grenadines, Dominica, Antigua and Barbuda, Bahamas, Barbados, Montserrat, St. Kitts and Nevis, Trinidad and Tobago)
HIV
Regional Coordinating Mechanism
Immediate approval
2
n/a
USD14,458,896
USD34,527,244
REDCARDÂ (re Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, Panama)
HIV
Regional organisation
Not approved
4
n/a
USD8,667,612
USD31,042,376
RedTraSex (re Argentina, Bolivia, Brazil, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay)
HIV
Regional organisation
Not approved
3
n/a
USD7,580,751
USD18,140,937
SADCÂ (re Angola, Botswana , Namibia, Zambia, Zimbabwe)
Malaria
Regional organisation
Not approved
4
n/a
USD8,183,343
USD12,571,057
SADCÂ (re Angola, Botswana, Congo (Democratic Republic), Lesotho, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, Swaziland , United Republic of Tanzania, Zambia, Zimbabwe)
HIV
Regional organisation
Delayed approval
2B
6
USD24,587,661
USD44,982,085
Based on advice from the TRP, the Board divided eligible Round 9 proposals into five Categories, as follows:
Table 5: Round 9 results by Category and Composite Index
Round 9 results by applicant were as in Tables 6 and 7, below.
Table 6: Round 9 Results, by Country
Note that for each grant, the final amount that will be approved will be on average at least 10% lower than the amount requested for years 1-2, and potentially up to 25% lower for years 3-5.
* Note that for Kenya TB, Senegal HIV, Serbia TB and Vietnam HIV, the amount requested is less than was in the proposal because the TRP removed certain elements from the proposal. Also for China TB the recommended amount was adjusted for other technical reasons.
Table 7: Round 9 results for regional applicants
- Category 1: Approved proposals requiring no or minor clarifications, which need to be provided within 8 weeks and then given a final approval by the TRP Chair and/or Vice-Chair.
- Category 2: Proposals that are approved in principle, subject to the required clarifications being provided within a limited timeframe (8 weeks for the applicant to provide an initial detailed response to the TRP queries, and a further 3 months to obtain the final TRP approval should further clarifications be requested). The TRP Chair and Vice-Chair need to give final approval.
- Category 2B: Proposals that are treated as those in Category 2, but are regarded as being relatively weak, on grounds of technical merit and/or issues of feasibility and likelihood of effective implementation.
- Category 3: Proposals not approved in their present form, though applicants are encouraged to resubmit in Round 10 following major revision.
- Category 4: Proposals that are rejected, with applicants not encouraged to resubmit in any similar form.
- Category 1 and Category 2 proposals are approved immediately.
- Each country submitting a proposal rated Category 2B is assigned a disease burden index of 4 or 1 according to whether the disease burden is "very high" or not "very high". And each such country is assigned a poverty index of 4, 2 or 0 according to whether the country is low income, lower-middle income, or upper-middle income. The sum of these two indexes creates the Composite Index, whose value is therefore between 8 and 1. The higher the country's Composite Index, the sooner its Category 2B proposal will be approved.
- Category 2B proposals will be approved in the following order, as pledges by donors to the Fund become available in the course of 2009-2010:
- Category 2B, Composite Index 8
- Category 2B, Composite Index 6
- Category 2B, Composite Index 5
- Category 2B, Composite Index 4
- Category 2B, Composite Index 3
Table 5: Round 9 results by Category and Composite Index
| Category and Composite Index | Number of proposals | Amount requested (Years 1-2) |
| Immediate approval: Category 1 | 5 | $0.14 b. |
| Immediate approval: Category 2 | 49 | $1.35 b. |
| Delayed approval: Category 2B, Composite Index 8 | 9 | $0.32 b. |
| Delayed approval: Category 2B, Composite Index 6 | 6 | $0.17 b. |
| Delayed approval: Category 2B, Composite Index 5 | 6 | $0.15 b. |
| Delayed approval: Category 2B, Composite Index 4 | 1 | $0.00 b. |
| Delayed approval: Category 2B, Composite Index 3 | 9 | $0.08 b. |
| Subtotal: All Approved Proposals: | 85 | $2.21 b. |
| Not Approved: Category 3 | 64 | $2.08 b. |
| Not Approved: Category 4 | 10 | $0.19 b. |
| Not Approved: Removed sub-components of approved proposals | n/a | $0.37 b. |
| Subtotal: All Non-Approved Proposals: | 74 | $2.63 b. |
| Total: All Proposals | 159 | $4.85 b. |
Note that for each grant, the final amount that will be approved will be on average at least 10% lower than the amount requested for years 1-2, and potentially up to 25% lower for years 3-5.
| Country | Disease component | Applicant type | Decision | Category (defined above) | Composite Index (defined above) | Amount requested (Years 1-2) | Amount requested (Years 1-5) |
| Afghanistan | HIVÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | USD17,157,661 | USD48,857,724 |
| Albania | HIV | CCM | Not approved | 3 | n/a | USD8,097,017 | USD13,275,254 |
| Albania | TB | CCM | Not approved | 3 | n/a | USD2,482,523 | USD5,226,962 |
| Angola | HIV | CCM | Not approved | 3 | n/a | USD37,442,140 | USD138,112,093 |
| Angola | TB | CCM | Delayed approval | 2B | 6 | USD11,384,314 | USD25,766,362 |
| Azerbaijan | HIV | CCM | Immediate approval | 2 | n/a | EUR11,831,706 | EUR26,983,960 |
| Azerbaijan | TB | CCM | Immediate approval | 2 | n/a | EUR1,983,042 | EUR5,065,216 |
| Bangladesh | Malaria | CCM | Immediate approval | 2 | n/a | USD10,280,071 | USD43,649,545 |
| Belarus | TB | CCM | Immediate approval | 2 | n/a | USD10,127,774 | USD24,679,591 |
| Belize | HIVÂ (disease part + HSS part) | CCM | Delayed approval | 2B | 4 | USD3,190,410 | USD6,053,270 |
| Benin | HIVÂ (disease part + HSS part) | CCM | Immediate approval | 2 | n/a | EUR48,272,734 | EUR108,636,826 |
| Benin | TB | CCM | Immediate approval | 2 | n/a | EUR2,813,599 | EUR4,815,146 |
| Bhutan | HIV | CCM | Not approved | 3 | n/a | USD1,277,902 | USD3,429,344 |
| Bolivia | HIV | CCM | Immediate approval | 2 | n/a | USD9,501,866 | USD26,267,794 |
| Bolivia | TB | CCM | Immediate approval | 2 | n/a | USD4,379,037 | USD9,833,163 |
| Bosnia & Herzegovina | HIV | CCM | Immediate approval | 2 | n/a | EUR14,428,659 | EUR32,453,777 |
| Bosnia & Herzegovina | TB | CCM | Delayed approval | 2B | 3 | EUR7,287,274 | EUR15,007,449 |
| Botswana | HIV | CCM | Not approved | 3 | n/a | USD22,137,763 | USD75,677,032 |
| Brazil | TB | CCM | Not approved | 3 | n/a | EUR26,499,742 | EUR57,157,477 |
| Brazil | HIV | CCM | Not approved | 3 | n/a | EUR13,097,142 | EUR30,940,720 |
| Burkina Faso | HIVÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | EUR49,925,705 | EUR160,561,226 |
| Burundi | Malaria | CCM | Immediate approval | 2 | n/a | USD21,578,809 | USD60,448,200 |
| Cambodia | HIVÂ (disease part + HSS part) | CCM | Immediate approval | 2 | n/a | USD63,502,281 | USD165,087,396 |
| Cambodia | Malaria | CCM | Immediate approval | 1 | n/a | USD43,717,857 | USD102,033,561 |
| Cameroon | HIV | CCM | Not approved | 3 | n/a | EUR41,336,332 | EUR121,255,912 |
| Cameroon | Malaria | CCM | Immediate approval | 2 | n/a | EUR77,791,996 | EUR113,983,337 |
| Cameroon | TB | CCM | Immediate approval | 2 | n/a | EUR6,823,011 | EUR15,422,473 |
| Central African Republic | TB | CCM | Delayed approval | 2B | 8 | EUR12,167,295 | EUR29,782,006 |
| Chad | HIVÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | EUR36,087,457 | EUR57,040,882 |
| Chad | Malaria | CCM | Immediate approval | 2 | n/a | EUR20,807,913 | EUR29,993,968 |
| Chad | TB | CCM | Not approved | 3 | n/a | EUR4,409,888 | EUR8,658,158 |
| China * | TBÂ (disease part + HSS part) | CCM | Delayed approval | 2B | 6 | USD76,075,195 | USD239,655,469 |
| Colombia | HIV | CCM | Delayed approval | 2B | 6 | EUR16,659,253 | EUR42,317,779 |
| Colombia | TB | CCM | Not approved | 3 | n/a | EUR6,981,414 | EUR13,155,213 |
| Comoros | HIVÂ (disease part + HSS part) | CCM | Immediate approval | 2 | n/a | EUR1,833,520 | EUR3,107,636 |
| Congo (Democratic Republic of) | HIV | CCM | Not approved | 3 | n/a | USD42,987,274 | USD94,181,440 |
| Congo (Democratic Republic of) | Malaria | CCM | Not approved | 3 | n/a | USD117,708,841 | USD280,495,135 |
| Congo (Democratic Republic of) | TBÂ (disease part + HSS part) | CCM | Delayed approval | 2B | 8 | USD110,092,302 | USD306,794,269 |
| Congo (Republic of) | HIV | CCM | Delayed approval | 2B | 6 | EUR10,773,466 | EUR27,447,268 |
| Cote d'Ivoire | HIVÂ (disease part) | CCM | Immediate approval | 2 | n/a | EUR46,066,302 | EUR125,953,322 |
| Cote d'Ivoire | HIVÂ (HSS part) | CCM | Not approved | n/a | n/a | EUR43,810,725 | EUR97,590,298 |
| Cote d'Ivoire | TB | CCM | Immediate approval | 2 | n/a | EUR9,672,256 | EUR33,977,331 |
| Djibouti | HIV | CCM | Not approved | 3 | n/a | EUR4,609,238 | EUR15,739,214 |
| Djibouti | Malaria | CCM | Delayed approval | 2B | 3 | EUR2,342,193 | EUR6,591,356 |
| Djibouti | TB | CCM | Not approved | 3 | n/a | EUR1,847,708 | EUR5,069,930 |
| Dominican Republic | HIV | CCM | Not approved | 3 | n/a | USD16,796,759 | USD49,481,694 |
| Ecuador | HIV | CCM | Immediate approval | 2 | n/a | USD10,813,915 | USD27,922,499 |
| Ecuador | TB | CCM | Immediate approval | 2 | n/a | USD6,834,160 | USD13,736,572 |
| El Salvador | TB | CCM | Immediate approval | 2 | n/a | USD3,588,887 | USD7,810,938 |
| Eritrea | Malaria (disease part + HSS part) | CCM | Immediate approval | 1 | n/a | USD29,855,990 | USD69,433,635 |
| Ethiopia | HIV | CCM | Not approved | 3 | n/a | USD38,910,498 | USD87,776,761 |
| Ethiopia | TBÂ (disease part) | CCM | Not approved | n/a | n/a | USD35,441,974 | USD99,748,261 |
| Ethiopia | TBÂ (HSS part) | CCM | Delayed approval | 2B | 8 | USD19,383,242 | USD38,601,776 |
| Fiji | HIVÂ (disease part) | CCM | Not approved | n/a | n/a | USD4,567,641 | USD11,032,725 |
| Fiji | HIVÂ (HSS part) | CCM | Immediate approval | 2 | n/a | USD1,242,510 | USD2,075,508 |
| Gambia | Malaria | CCM | Immediate approval | 2 | n/a | USD10,611,436 | USD26,346,040 |
| Gambia | TB | CCM | Delayed approval | 2B | 5 | USD8,049,144 | USD15,626,486 |
| Georgia | HIV | CCM | Immediate approval | 1 | n/a | EUR7,209,605 | EUR12,826,501 |
| Georgia | TB | CCM | Not approved | 3 | n/a | EUR6,334,105 | EUR15,198,017 |
| Ghana | TBÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | USD35,221,971 | USD78,630,160 |
| Guatemala | Malaria | CCM | Immediate approval | 2 | n/a | USD21,452,001 | USD42,171,298 |
| Guinea | Malaria | CCM | Not approved | 3 | n/a | USD41,713,830 | USD136,406,368 |
| Guinea | TB | CCM | Immediate approval | 2 | n/a | USD4,035,589 | USD10,736,627 |
| Guinea | HIVÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | USD47,536,996 | USD133,700,829 |
| Guinea-Bissau | Malaria (disease part + HSS part) | CCM | Immediate approval | 2 | n/a | EUR6,145,091 | EUR13,492,563 |
| Guinea-Bissau | TB | CCM | Delayed approval | 2B | 5 | EUR7,179,501 | EUR14,553,382 |
| Haiti | TB | CCM | Delayed approval | 2B | 8 | USD12,260,870 | USD27,669,547 |
| Honduras | HIV | CCM | Immediate approval | 2 | n/a | USD9,821,491 | USD21,899,375 |
| Honduras | TB | CCM | Not approved | 3 | n/a | USD4,644,621 | USD7,973,129 |
| India | HIV | CCM | Delayed approval | 2B | 8 | USD21,000,206 | USD78,712,640 |
| India | Malaria | CCM | Delayed approval | 2B | 5 | USD38,105,605 | USD113,680,179 |
| India | TB | CCM | Immediate approval | 2 | n/a | USD69,477,410 | USD199,544,948 |
| Indonesia | HIVÂ (disease part) | CCM | Immediate approval | 2 | n/a | USD27,723,275 | USD87,142,130 |
| Indonesia | HIVÂ (HSS part) | CCM | Not approved | n/a | n/a | USD16,211,864 | USD34,683,394 |
| Iraq | TB | CCM | Delayed approval | 2B | 3 | USD14,670,783 | USD28,785,292 |
| Kenya | Malaria | CCM | Not approved | 3 | n/a | USD173,151,886 | USD270,264,819 |
| Kenya * | TB | CCM | Delayed approval | 2B | 8 | USD23,682,114 | USD50,661,608 |
| Korea (Democratic People's Republic of) | HIV | CCM | Not approved | 4 | n/a | EUR3,621,666 | EUR10,260,105 |
| Kosovo | TB | CCM | Delayed approval | 2B | 3 | EUR2,784,907 | EUR5,821,665 |
| Kyrgyz Republic | TB | CCM | Delayed approval | 2B | 5 | USD7,811,886 | USD26,273,558 |
| Lesotho | HIV | CCM | Immediate approval | 2 | n/a | USD10,356,112 | USD30,796,293 |
| Liberia | TB | CCM | Not approved | 3 | n/a | USD24,337,864 | USD54,637,458 |
| Macedonia, FYR | TB | CCM | Not approved | 3 | n/a | EUR2,406,848 | EUR4,846,058 |
| Malawi | Malaria | CCM | Immediate approval | 2 | n/a | USD33,170,946 | USD94,006,593 |
| Malawi | TBÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | USD16,586,861 | USD34,091,794 |
| Malaysia | HIV | CCM | Not approved | 3 | n/a | EUR16,914,686 | EUR55,470,594 |
| Mali | Malaria | CCM | Not approved | 3 | n/a | EUR78,261,962 | EUR174,578,758 |
| Mexico | HIV | CCM | Immediate approval | 2 | n/a | USD31,008,826 | USD76,492,174 |
| Moldova | HIV | CCM | Not approved | 3 | n/a | EUR6,632,255 | EUR6,632,255 |
| Moldova | TB | CCM | Delayed approval | 2B | 3 | EUR5,271,784 | EUR10,099,233 |
| Mongolia | HIVÂ (disease part) | CCM | Not approved | n/a | n/a | USD2,117,412 | USD5,236,283 |
| Mongolia | HIVÂ (HSS part) | CCM | Immediate approval | 2 | n/a | USD2,780,049 | USD4,223,964 |
| Montenegro | HIV | CCM | Delayed approval | 2B | 3 | EUR2,547,414 | EUR5,164,889 |
| Montenegro | TB | CCM | Not approved | 3 | n/a | EUR1,079,081 | EUR1,825,708 |
| Mozambique | HIVÂ (disease part) | CCM | Delayed approval | 2B | 8 | USD69,377,979 | USD175,774,009 |
| Mozambique | HIVÂ (HSS part) | CCM | Not approved | n/a | n/a | USD32,700,132 | USD87,121,662 |
| Mozambique | Malaria | CCM | Immediate approval | 2 | n/a | USD67,401,102 | USD157,490,802 |
| Myanmar | HIV | CCM | Immediate approval | 1 | n/a | USD51,716,207 | USD157,776,471 |
| Myanmar | Malaria | CCM | Immediate approval | 2 | n/a | USD37,578,282 | USD77,384,020 |
| Myanmar | TB | CCM | Immediate approval | 2 | n/a | USD34,024,424 | USD85,520,947 |
| Nepal | HIV | CCM | Not approved | 3 | n/a | USD10,250,156 | USD33,295,636 |
| Nicaragua | Malaria | CCM | Delayed approval | 2B | 3 | USD4,299,868 | USD8,204,092 |
| Niger | HIV | CCM | Not approved | 3 | n/a | EUR12,273,273 | EUR35,668,229 |
| Niger | Malaria | CCM | Not approved | 3 | n/a | EUR14,774,509 | EUR60,296,247 |
| Niger | TBÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | EUR28,683,728 | EUR51,445,595 |
| Nigeria | HIV | CCM | Immediate approval | 2 | n/a | USD61,980,496 | USD341,019,908 |
| Nigeria | TB | CCM | Delayed approval | 2B | 8 | USD31,515,160 | USD113,332,101 |
| Pakistan | HIVÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | USD34,771,776 | USD101,928,849 |
| Pakistan | Malaria | CCM | Not approved | 3 | n/a | USD22,058,072 | USD38,444,514 |
| Pakistan | TB | CCM | Immediate approval | 2 | n/a | USD40,146,549 | USD173,045,676 |
| Panama | HIVÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | USD8,681,679 | USD19,791,821 |
| Papua New Guinea | HIVÂ (disease part + HSS part) | CCM | Not approved | 3 | n/a | USD37,755,778 | USD108,875,287 |
| Paraguay | HIVÂ (disease part) | CCM | Not approved | n/a | n/a | USD6,924,331 | USD16,738,249 |
| Paraguay | HIVÂ (HSS part) | CCM | Immediate approval | 2 | n/a | USD6,463,831 | USD12,735,212 |
| Paraguay | TB | CCM | Immediate approval | 2 | n/a | USD2,080,336 | USD3,974,941 |
| Peru | Malaria | CCM | Not approved | 3 | n/a | EUR12,287,854 | EUR23,978,876 |
| Russian Federation | TB | CCM | Not approved | 4 | n/a | EUR39,148,932 | EUR139,266,200 |
| Russian Federation | TB | Sub-CCM | Not approved | 4 | n/a | EUR25,586,216 | EUR46,500,983 |
| São Tomé and PrÃncipe | HIV | CCM | Not approved | 3 | n/a | USD3,388,782 | USD5,893,968 |
| Senegal * | HIVÂ (disease part + HSS part) | CCM | Immediate approval | 2 | n/a | EUR29,125,467 | EUR88,751,831 |
| Senegal | Malaria | CCM | Not approved | 3 | n/a | EUR13,463,444 | EUR43,391,628 |
| Senegal | TB | CCM | Not approved | 3 | n/a | EUR5,439,361 | EUR15,223,424 |
| Serbia * | TB | CCM | Immediate approval | 1 | n/a | USD3,441,632 | USD7,540,351 |
| Sierra Leone | HIVÂ (disease part + HSS part) | CCM | Immediate approval | 2 | n/a | USD35,159,372 | USD86,543,306 |
| Sierra Leone | Malaria | CCM | Not approved | 3 | n/a | USD46,897,411 | USD121,926,865 |
| Solomon Islands | HIV | CCM | Not approved | 3 | n/a | USD6,896,921 | USD17,219,358 |
| South Africa | HIV | CCM | Immediate approval | 2 | n/a | USD42,577,518 | USD108,974,360 |
| Sri Lanka | HIVÂ (disease part + HSS part) | CCM | Delayed approval | 2B | 3 | USD19,398,656 | USD34,901,359 |
| Sudan South | HIVÂ (disease part) | Sub-CCM | Not approved | n/a | n/a | USD59,977,815 | USD143,281,740 |
| Sudan South | HIVÂ (HSS part) | Sub-CCM | Immediate approval | 2 | n/a | USD27,230,100 | USD52,572,614 |
| Sudan South | Malaria | CCM | Not approved | 3 | n/a | USD47,848,374 | USD130,852,071 |
| Suriname | HIV | CCM | Not approved | 3 | n/a | USD13,973,874 | USD30,918,273 |
| Suriname | TB | CCM | Immediate approval | 2 | n/a | USD3,112,254 | USD5,765,300 |
| Syria | HIVÂ (disease part + HSS part) | CCM | Not approved | 4 | n/a | USD12,748,562 | USD25,664,260 |
| Syria | TB | CCM | Not approved | 4 | n/a | USD4,632,686 | USD9,343,366 |
| Tanzania | HIVÂ (disease part) | CCM | Not approved | n/a | n/a | USD141,703,169 | USD299,064,874 |
| Tanzania | HIVÂ (HSS part) | CCM | Immediate approval | 2 | n/a | USD97,901,945 | USD176,089,978 |
| Tanzania | Malaria | CCM | Delayed approval | 2B | 5 | USD76,050,523 | USD173,612,609 |
| Tanzania | TB | CCM | Not approved | 3 | n/a | USD44,045,185 | USD99,426,802 |
| Thailand | HIV | CCM | Not approved | 3 | n/a | USD22,903,685 | USD68,935,356 |
| Thailand | Malaria | CCM | Not approved | 3 | n/a | USD32,327,332 | USD75,648,892 |
| Togo | HIV | CCM | Not approved | 3 | n/a | EUR19,855,192 | EUR54,839,797 |
| Togo | Malaria (disease part) | CCM | Immediate approval | 2 | n/a | EUR41,116,176 | EUR70,116,448 |
| Togo | Malaria (HSS part) | CCM | Not approved | n/a | n/a | EUR2,424,256 | EUR5,369,974 |
| Togo | TB | CCM | Not approved | 4 | n/a | EUR1,904,955 | EUR1,904,955 |
| Turkmenistan | TBÂ (disease part) | CCM | Delayed approval | 2B | 3 | USD7,268,169 | USD19,186,023 |
| Turkmenistan | TBÂ (HSS part) | CCM | Not approved | n/a | n/a | USD181,777 | USD289,542 |
| Uganda | HIV | CCM | Not approved | 3 | n/a | USD200,824,716 | USD411,140,514 |
| Uganda | Malaria (disease part + HSS part) | CCM | Not approved | 3 | n/a | USD135,054,987 | USD376,353,583 |
| Uganda | TB | CCM | Not approved | 3 | n/a | USD20,327,175 | USD32,684,978 |
| Ukraine | TB | CCM | Not approved | 3 | n/a | USD34,584,205 | USD103,459,618 |
| Uruguay | HIV | CCM | Not approved | 3 | n/a | USD7,679,330 | USD24,664,893 |
| Vietnam * | HIV | CCM | Immediate approval | 2 | n/a | USD27,363,443 | USD101,950,596 |
| Vietnam | TB | CCM | Delayed approval | 2B | 8 | USD19,124,977 | USD59,392,208 |
| Yemen | HIV | CCM | Not approved | 3 | n/a | USD10,943,780 | USD25,246,321 |
| Yemen | TB | CCM | Delayed approval | 2B | 5 | USD11,136,828 | USD24,769,339 |
| Zambia | HIV | CCM | Not approved | 3 | n/a | USD26,111,595 | USD142,597,930 |
| Zambia | Malaria | CCM | Not approved | 3 | n/a | USD21,843,651 | USD54,966,386 |
Table 7: Round 9 results for regional applicants
| Applicant | Disease | Applicant type | Decision | Category (defined above) | Composite Index (defined above) | Requested (Years 1-2) | Requested (Years 1-5) |
| AfriCASOÂ (re Benin, Cameroon, Central African Republic, Gabon, Gambia, Liberia) | HIV | Regional organisation | Not approved | 3 | n/a | EUR5,894,744 | EUR13,672,440 |
| Andean Regional Coordinating Mechanism (re Chile, Peru, Colombia, Bolivia, Ecuador, Venezuela) | HIV | Regional Coordinating Mechanism | Not approved | 4 | n/a | EUR19,820,520 | EUR40,189,363 |
| CCLABÂ (re Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama) | HIV | Regional Coordinating Mechanism | Not approved | 3 | n/a | USD11,123,412 | USD18,721,697 |
| COPRECOS LACÂ (re Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Nicaragua, Panama, Paraguay, Peru, Uruguay, Venezuela) | HIV | Regional organisation | Delayed approval | 2B | 6 | USD17,599,678 | USD58,889,550 |
| Mano River Union (re Côte d'Ivoire, Guinea, Liberia, Sierra Leone) | HIV | Regional organisation | Not approved | 4 | n/a | USD21,688,571 | USD36,300,171 |
| MENAHRAÂ (re Afghanistan, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, West Bank and Gaza, Pakistan, Syrian Arab Republic, Tunisia) | HIV | Regional organisation | Not approved | 3 | n/a | USD15,196,689 | USD32,966,023 |
| Naz Foundation Int. (re Afghanistan, Bangladesh, Bhutan, India, Nepal, Pakistan, Sri Lanka) | HIV | Regional organisation | Immediate approval | 2 | n/a | USD18,660,775 | USD47,002,257 |
| PANCAP-CARICOMÂ (re Haiti, Dominican Republic, Guyana, Jamaica, Suriname, Belize, Dominica, Grenada, St. Lucia, St Vincent and the Grenadines, Dominica, Antigua and Barbuda, Bahamas, Barbados, Montserrat, St. Kitts and Nevis, Trinidad and Tobago) | HIV | Regional Coordinating Mechanism | Immediate approval | 2 | n/a | USD14,458,896 | USD34,527,244 |
| REDCARDÂ (re Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, Panama) | HIV | Regional organisation | Not approved | 4 | n/a | USD8,667,612 | USD31,042,376 |
| RedTraSex (re Argentina, Bolivia, Brazil, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay) | HIV | Regional organisation | Not approved | 3 | n/a | USD7,580,751 | USD18,140,937 |
| SADCÂ (re Angola, Botswana , Namibia, Zambia, Zimbabwe) | Malaria | Regional organisation | Not approved | 4 | n/a | USD8,183,343 | USD12,571,057 |
| SADCÂ (re Angola, Botswana, Congo (Democratic Republic), Lesotho, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, Swaziland , United Republic of Tanzania, Zambia, Zimbabwe) | HIV | Regional organisation | Delayed approval | 2B | 6 | USD24,587,661 | USD44,982,085 |
Publication Date:
2009-11-12
